Hand, foot and mouth disease (HFMD) is a common infectious disease among children, and has emerged as a substantial global public health concern, particularly in the Asia-Pacific region. It has a serious impact on children′s health and imposes a significant disease burden on families and society. Currently, there are three globally available HFMD vaccines (all of them are EV71 inactivated vaccine), which were first approved and marketed in China in 2016. Real-world studies have shown a decrease in the incidence, severity, and mortality rate of EV71-related HFMD, providing evidence of its effectiveness. Additionally, related data have indicated a significant change in the pathogen spectrum of HFMD in China in the post-vaccine era. This article aims to provide a comprehensive review of the safety, effectiveness and immune-persistence data of EV71 vaccine acquired through real-world studies.

Stapled peptides with significantly enhanced pharmacological profiles have emerged as promising therapeutic molecules due to their remarkable resistance to proteolysis and performance to penetrate cells. The all-hydrocarbon peptide stapling technique has already widely adopted with great success, yielding numerous potent peptide-based molecules. Based on our prior efforts, we conceived and prepared a double-stapled peptide in this study, termed FRNC-1, which effectively attenuated the bone resorption capacity of mature osteoclasts in vitro through specific inhibition of phosphorylated GSK-3β. The double-stapled peptide FRNC-1 displayed notably improved helical contents and resistance to proteolysis than its linear form. Additionally, FRNC-1 effectively prevented osteoclast activation and improved bone density for ovariectomized (OVX) mice after intravenous injection and importantly, after oral (intragastric) administration. The double-stapled peptide FRNC-1 is the first orally effective peptide that has been validated to date as a therapeutic candidate for postmenopausal osteoporosis (PMOP).